Novo Nordisk

Saxenda

Liraglutide 3.0 mg

First-generation daily GLP-1 for weight management — effective but superseded.

Chronic Weight Management ~8% avg weight loss

68 C+

Response Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

Saxenda (liraglutide 3.0 mg) is a once-daily GLP-1 receptor agonist approved for chronic weight management. As the predecessor to Wegovy in the GLP-1 weight-management space, it established the therapeutic class but has been largely superseded by once-weekly semaglutide and tirzepatide formulations that offer greater efficacy and more convenient dosing.

Mechanism of Action

Liraglutide is a GLP-1 analog with 97% homology to native human GLP-1. It activates the GLP-1 receptor to enhance insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite. The 3.0 mg weight-management dose provides stronger appetite suppression than the 1.8 mg diabetes dose (Victoza), though the short half-life requires daily injection.

Clinical Evidence

The SCALE trial program showed approximately 8% mean body weight reduction over 56 weeks with liraglutide 3.0 mg versus ~2.6% with placebo. While statistically and clinically significant, this is substantially less than the 15–22% achieved with newer agents. The LEADER trial (Victoza 1.8 mg) demonstrated cardiovascular benefit, but this was at the diabetes dose, not the weight-management dose.

mRNA Monitoring Insight

Liraglutide's transcriptomic profile is less extensively characterized than semaglutide's in the obesity context. However, core GLP-1 pathway gene targets overlap. Biomeme's mRNA monitoring can track inflammatory and metabolic markers, though the signal magnitude may be smaller given the lower weight loss efficacy. For patients on Saxenda, mRNA monitoring provides valuable confirmation that molecular pathways are engaging, even if clinical changes are more gradual.

Side Effects & Safety

Nausea (39%), diarrhea, constipation, vomiting, and injection site reactions are common. The daily injection requirement is a significant convenience disadvantage compared to weekly alternatives. Rare risks include pancreatitis, gallbladder disease, and the thyroid C-cell tumor warning common to GLP-1 agonists.

FAQ

Should I switch from Saxenda to Wegovy or Mounjaro?

Many clinicians are transitioning patients from Saxenda to weekly GLP-1 options. Wegovy and Mounjaro offer greater weight loss efficacy and weekly dosing convenience. However, Saxenda may still be appropriate for patients who respond well to it or have insurance coverage constraints.

Quick Facts

Generic: Liraglutide 3.0 mg
Manufacturer: Novo Nordisk
Key Trial: SCALE
Score: 68/100 (C+)

Sources

[1] SCALE Trial — NEJM 2015

Compare Others

Track Your Saxenda Response.

Biomeme's GLP-1 Response Panel monitors molecular changes so you know your medication is working — weeks before the scale moves.